The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bezuclastinib in combination with Sutent (sunitinib) for adults with advanced gastrointestinal stromal tumors (GIST) whose disease has progressed on, or become resistant to, GLEEVEC (imatinib), according to a recent update from Cogent Biosciences.
This regulatory milestone positions the bezuclastinib–Sutent combination as a promising new targeted therapy option in the second-line GIST setting, an area that has seen little innovation for more than two decades.
Breakthrough Therapy Designation Highlights Potential to Transform Second-Line GIST Treatment
Breakthrough Therapy Designation is reserved for investigational therapies that treat serious or life-threatening conditions and show preliminary clinical evidence of substantial improvement over available therapies on one or more clinically meaningful endpoints.
For patients with GLEEVEC-resistant or -intolerant GIST, current standard second-line treatment with sunitinib alone can provide disease control, but responses are often modest and temporary. By granting this designation, the FDA is signaling that early data for bezuclastinib plus Sutent may represent a significant step forward compared with existing options in this high‑unmet‑need population.
Executives at Cogent Biosciences noted that the designation acknowledges the potential of the bezuclastinib combination to meaningfully improve outcomes for patients with GLEEVEC-resistant GIST and underscores the urgency of bringing the first new second-line treatment option in over 20 years to market.
Bezuclastinib + Sutent: Key Phase 3 PEAK Trial Results in Advanced GIST
The Breakthrough Therapy Designation is supported by positive findings from the phase 3 PEAK trial, which evaluated bezuclastinib plus Sutent versus Sutent alone in patients with advanced GIST previously treated with GLEEVEC.
In the PEAK study:
- The combination of bezuclastinib and Sutent reduced the risk of disease progression or death by approximately 50% compared with Sutent monotherapy.
- Median progression-free survival (PFS) reached 16.5 months with the combination versus 9.2 months for Sutent alone, based on blinded independent central review.
- The PFS benefit was both statistically significant and clinically meaningful, suggesting more durable disease control in a population with limited remaining options.
Importantly, the safety profile of the regimen appeared manageable. Investigators reported that the addition of bezuclastinib did not introduce unexpected safety signals beyond the known toxicity profile of Sutent, supporting the feasibility of combining these agents in routine practice if approved.
Progression-free survival was the primary endpoint of the PEAK trial, reflecting the length of time patients lived without their cancer worsening. This endpoint is particularly relevant in advanced GIST, where prolonged disease control without excessive toxicity can translate into meaningful gains in quality of life.
Addressing Unmet Need in GLEEVEC-Resistant Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors are rare mesenchymal tumors of the digestive tract, frequently driven by activating mutations in the KIT or PDGFRA genes. GLEEVEC (imatinib) revolutionized the management of GIST as a first-line targeted therapy, dramatically improving survival for many patients.
However, most patients eventually develop secondary resistance mutations, leading to disease progression despite continued imatinib treatment. Sutent (sunitinib) is currently a common second-line tyrosine kinase inhibitor (TKI) option, yet its benefits can be modest and time-limited, and patients often cycle through multiple TKIs as resistance accumulates.
By selectively targeting key oncogenic drivers, bezuclastinib in combination with Sutent aims to offer more durable control of GIST after GLEEVEC failure, potentially redefining the standard of care in the second-line setting.
For an in-depth analysis of Gastrointestinal Stromal Tumors market and its unmet needs, download Gastrointestinal Stromal Tumors Market Insights report.
Regulatory Momentum: Real-Time Oncology Review and NDA Timeline
In addition to Breakthrough Therapy Designation, the FDA has agreed to review Cogent Biosciences’ new drug application (NDA) for the bezuclastinib–Sutent combination under the Real-Time Oncology Review (RTOR) program.
RTOR allows the agency to evaluate key clinical data components of an NDA on a rolling basis, prior to the formal submission of the complete application. This approach is designed to streamline and potentially accelerate the review process for oncology drugs that may offer meaningful improvements over existing treatments.
According to Cogent Biosciences:
- The company expects to complete the full NDA submission by April 2026.
- Detailed results from the phase 3 PEAK trial are planned for presentation at a major medical meeting in the first half of 2026, which will provide the oncology community with a deeper look at efficacy, safety, and subgroup analyses.
While FDA approval is not guaranteed, the combination of Breakthrough Therapy Designation and Real-Time Oncology Review suggests that regulators view the therapy as a potentially important advance for patients with advanced GIST.
Next Steps in Clinical Development: Expansion Into Earlier Lines and Molecularly Defined GIST
Cogent Biosciences also plans to broaden the clinical development of bezuclastinib in GIST. A phase 2 trial is expected to begin in mid‑2026, evaluating the combination in patients with exon 9–mutated GIST who are either treatment‑naïve or recently initiated on GLEEVEC.
Targeting exon 9–mutated disease earlier in the treatment journey may help clarify the role of bezuclastinib + Sutent in molecularly defined subgroups and potentially support expansion into front‑line or early‑line settings if data remain favorable.
This strategy aligns with broader precision oncology trends in GIST treatment, where tailoring therapy based on mutation status (such as KIT exon 9, exon 11, or PDGFRA mutations) is increasingly central to optimizing outcomes.
Implications for Patients, Clinicians, and the GIST Treatment Landscape
If ultimately approved, bezuclastinib in combination with Sutent could become:
- The first new second-line treatment option for GLEEVEC-resistant GIST in more than 20 years
- A new standard of care in advanced GIST after imatinib failure, with superior progression-free survival compared with sunitinib alone
- A foundation for further combination strategies and mutation-directed approaches in GIST management
For oncologists, the availability of additional targeted therapy options with strong PFS data would provide more flexibility in designing treatment sequences and tailoring care to individual patient and molecular profiles. For patients and caregivers, longer disease control with a manageable safety profile may translate into extended time on effective therapy with preserved quality of life.
Summary
The FDA’s Breakthrough Therapy Designation for bezuclastinib plus Sutent in advanced, GLEEVEC-resistant gastrointestinal stromal tumors marks an important regulatory and clinical milestone in GIST treatment. Backed by phase 3 PEAK trial data showing a 50% reduction in the risk of disease progression or death and a median PFS of 16.5 months versus 9.2 months on Sutent alone, the combination is emerging as a potentially practice‑changing regimen in the second‑line setting.
With Real-Time Oncology Review underway and an NDA expected to be fully submitted by April 2026, the oncology community will be closely watching upcoming data presentations and regulatory updates to see whether this novel combination can reshape the standard of care for patients living with advanced GIST.
Learn more about the evolving Gastrointestinal Stromal Tumors treatment landscape with DelveInsight’s latest report on Gastrointestinal Stromal Tumors Market Insights.
